Lumiracoxib
- Generic Name
- Lumiracoxib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H13ClFNO2
- CAS Number
- 220991-20-8
- Unique Ingredient Identifier
- V91T9204HU
- Background
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
- Indication
For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.
- Associated Conditions
- -
- Associated Therapies
- -
Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Hospital Central Sur de Pemex
- Target Recruit Count
- 28
- Registration Number
- NCT01481610
- Locations
- 🇲🇽
Hospital Central Sur de Alta Especialidad PEMEX, Mexico City, DF, Mexico
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
- Conditions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1312
- Registration Number
- NCT00476034
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)
- Conditions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 833
- Registration Number
- NCT00475800
- Locations
- 🇨🇦
Novartis Investigative Site, Brampton, Ontario, Canada
Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension
- Conditions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 78
- Registration Number
- NCT00419796
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
- Conditions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1464
- Registration Number
- NCT00366938
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, E. Hanover, New Jersey, United States
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
- Conditions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1684
- Registration Number
- NCT00367315
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel
- Conditions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00350155
Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib
- Conditions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 364
- Registration Number
- NCT00348491
- Locations
- 🇺🇸
Dental Research Clinic, Austin, Texas, United States
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
- Conditions
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 110
- Registration Number
- NCT00333567
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension
- Conditions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1020
- Registration Number
- NCT00267176
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
🇺🇸Southern Illinois Clinical Research, O'Fallon, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.